Table 5 Clinical and laboratory outcomes of patients who were given rupatadine 40 mg either ≤3 days of illness or later.
From: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection
Rupatadine 40 mg Recruited ≤3 days N = 17 | Rupatadine 40 mg Recruited >3 days N = 49 | P value | |
|---|---|---|---|
Ascites by Ultra sound scan (%) | 4 (23.5) | 11 (22.4) | 1.0 |
Extent of Ascites as measured by US Scan | |||
Mild (%) | 3 (17.6) | 2 (4.1) | |
Moderate (%) | 1 (5.9) | 9 (18.4) | 0.4 |
Pleural effusion by Ultra Sound Scan (%) | 1 (5.9) | 6 (12.2) | 0.7 |
Haematocrit >20% rise from baseline | 1 (5.9) | 8 (16.3) | 0.4 |
Duration of illness | |||
Median (IQR) | 7 (5.5 to 7) | 7 (6.5 to 8) | |
Mean (SD±) | 6.3 (1.5) | 7.3 (1.4) | 0.03 |
Given dextran (%) | 1 (5.9) | 5 (10.2) | 1.0 |
Exceeded the fluid quota (%) | 4 (23.5) | 12 (24.5) | 1.0 |
Quantity of extra fluid given | |||
Median (IQR) | 300 (231.3 to 627.5) | 362 (281.3 to 812.5) | 0.4 |
Hepatitis (ALT > 250/L) (%) | 0 (0) | 3 (6.1) | 0.56 |
High ALT (>200 U/L) (%) | 1 (5.9) | 8 (16.3) | 0.4 |
High AST (>200 U/L) (%) | 1 (5.9) | 13 (26.5) | 0.09 |
Bleeding (%) | 2 (11.7) | 0 (0) | 0.06 |
Low platelet counts | |||
<20 × 109/L (%) | 2 (11.7) | 10 (20.4) | 0.7 |
20 to 50 × 109/L (%) | 7 (41.2) | 10 (20.4) | 0.4 |
